BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 26109433)

  • 21. Autophagy protein p62/SQSTM1 is involved in HAMLET-induced cell death by modulating apotosis in U87MG cells.
    Zhang YB; Gong JL; Xing TY; Zheng SP; Ding W
    Cell Death Dis; 2013 Mar; 4(3):e550. PubMed ID: 23519119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
    Zang Y; Thomas SM; Chan ET; Kirk CJ; Freilino ML; DeLancey HM; Grandis JR; Li C; Johnson DE
    Autophagy; 2012 Dec; 8(12):1873-4. PubMed ID: 22995770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p62/SQSTM1 is involved in caspase-8 associated cell death induced by proteasome inhibitor MG132 in U87MG cells.
    Zeng RX; Zhang YB; Fan Y; Wu GL
    Cell Biol Int; 2014 Oct; 38(10):1221-6. PubMed ID: 24805111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance.
    Jia Y; Zhang W; Liu H; Peng L; Yang Z; Lou J
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):377-85. PubMed ID: 21833590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
    Rosebeck S; Alonge MM; Kandarpa M; Mayampurath A; Volchenboum SL; Jasielec J; Dytfeld D; Maxwell SP; Kraftson SJ; McCauley D; Shacham S; Kauffman M; Jakubowiak AJ
    Mol Cancer Ther; 2016 Jan; 15(1):60-71. PubMed ID: 26637366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dehydroepiandrosterone triggers autophagic cell death in human hepatoma cell line HepG2 via JNK-mediated p62/SQSTM1 expression.
    Vegliante R; Desideri E; Di Leo L; Ciriolo MR
    Carcinogenesis; 2016 Mar; 37(3):233-44. PubMed ID: 26762228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells.
    Thompson HG; Harris JW; Wold BJ; Lin F; Brody JP
    Oncogene; 2003 Apr; 22(15):2322-33. PubMed ID: 12700667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
    Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
    Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response.
    Zhang Y; Cheng Y; Ren X; Zhang L; Yap KL; Wu H; Patel R; Liu D; Qin ZH; Shih IM; Yang JM
    Oncogene; 2012 Feb; 31(8):1055-64. PubMed ID: 21743489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
    Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
    J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation.
    Tucci M; Stucci S; Savonarola A; Resta L; Cives M; Rossi R; Silvestris F
    Exp Hematol; 2014 Oct; 42(10):897-908.e1. PubMed ID: 24971696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenomics and chemical library screens reveal a novel SCF
    Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
    Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis.
    Carew JS; Espitia CM; Esquivel JA; Mahalingam D; Kelly KR; Reddy G; Giles FJ; Nawrocki ST
    J Biol Chem; 2011 Feb; 286(8):6602-13. PubMed ID: 21148553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs.
    Byrgazov K; Kraus M; Besse A; Slipicevic A; Lehmann F; Driessen C; Besse L
    Leuk Res; 2021 Feb; 101():106499. PubMed ID: 33422770
    [No Abstract]   [Full Text] [Related]  

  • 35. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
    Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
    J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
    Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
    Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations.
    Hua F; Li K; Yu JJ; Lv XX; Yan J; Zhang XW; Sun W; Lin H; Shang S; Wang F; Cui B; Mu R; Huang B; Jiang JD; Hu ZW
    Nat Commun; 2015 Aug; 6():7951. PubMed ID: 26268733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cleavage of sequestosome 1/p62 by an enteroviral protease results in disrupted selective autophagy and impaired NFKB signaling.
    Shi J; Wong J; Piesik P; Fung G; Zhang J; Jagdeo J; Li X; Jan E; Luo H
    Autophagy; 2013 Oct; 9(10):1591-603. PubMed ID: 23989536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.
    Schäfer J; Welti L; Seckinger A; Burhenne J; Theile D; Weiss J
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):71-79. PubMed ID: 28500557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
    Muz B; Kusdono HD; Azab F; de la Puente P; Federico C; Fiala M; Vij R; Salama NN; Azab AK
    Leuk Lymphoma; 2017 Dec; 58(12):2916-2925. PubMed ID: 28509582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.